Abstract
Objectives. We explored clinical factors associated with a major response to rituximab (RTX) (e.g. ACR 550, and European League against Rheumatism (EULAR) moderate to good response) in patients with active long-standing RA and inadequate response to anti-TNF agents or traditional DMARDs. Methods. RTX was used in 110 RA patients in six different Italian centres. The mean disease activity score on 28 joints (DAS28) was 6.4±0.99 and the mean HAQ was 1.63±0.68 at baseline. Thirty-two patients (29.1%) underwent RTX after the failure of DMARD therapy, 37 (33.6%) had failed or were intolerant to at least two anti-TNF agents, and 41 (37.3%) had failed or were intolerant to one anti-TNF agent. Univariate and multivariate analyses were performed. Results. The number of previous anti-TNF agents (P=0.043), HAQ (P=0.023), RF positivity (P
Original language | English |
---|---|
Pages (from-to) | 1557-1559 |
Number of pages | 3 |
Journal | Rheumatology |
Volume | 48 |
Issue number | 12 |
DOIs | |
Publication status | Published - 2009 |
Keywords
- Anti-CCP
- Anti-TNF
- DMARDs
- Rheumatoid arthritis
- Rheumatoid factor
- Rituximab
ASJC Scopus subject areas
- Rheumatology
- Pharmacology (medical)